Rezolute Q4 net loss narrows as R&D expenses fall
RZLT•Rezolute’s fiscal fourth-quarter net loss narrowed year over year to $20.49 million, or $0.20 per share, as research and development expenses fell, mainly because of lower manufacturing costs for ersodetug. The company expects topline results from its upLIFT Phase 3 tumor HI study before the end of 2026.
1. Quarterly results
Rezolute reported a fiscal fourth-quarter net loss of $20.49 million, or $0.20 per share, with operating expenses of $21.56 million. Research and development expenses declined, primarily due to lower manufacturing costs for ersodetug, while general and administrative expenses rose because of higher employee-related stock-based compensation and professional fees.
2. Study updates
The company expects topline results from its upLIFT Phase 3 tumor HI study before the end of 2026 and is awaiting FDA feedback on the sunRIZE study for congenital HI.
